Stryker Corporation
SYK
$281.87
+2.29%
Stryker Corporation designs, manufactures, and markets medical equipment, instruments, consumable supplies, and implantable devices, spanning reconstructive orthopaedics (hip and knee replacements, extremities), MedSurg (endoscopy systems, operating room equipment, hospital beds and gurneys), and neurovascular (embolic coils, mechanical thrombectomy systems), with roughly one-fourth of revenue generated outside the United States. As one of the three largest competitors in reconstructive orthopedic implants and the clear leader in operating room equipment, Stryker is best characterized as a scaled, diversified med-tech compounder rather than a single-product story, competing primarily with Zimmer Biomet, Johnson & Johnson MedTech, and Boston Scientific across overlapping categories. The current investor narrative has turned sharply cautious: despite completing the acquisition of Amplitude Vascular Systems in May 2026 to add next-generation intravascular lithotripsy technology to its peripheral vascular portfolio, the stock has de-rated violently, with shares down roughly 29% over the past year and nearly 21% in the last month alone, badly lagging a healthcare sector that itself has faced tariff and procedure-volume uncertainty. The debate now centers on whether this is a temporary sentiment-driven dislocation in a high-quality franchise or the early stage of a genuine fundamental slowdown, particularly given decelerating top-line growth (Q1 2026 revenue up just 2.6% year over year) and a compressed forward multiple that implies the market is pricing in meaningful earnings risk.…
SYK
Stryker Corporation
$281.87
Related headlines
Investment Opinion: Should I buy SYK Today?
Rating: Hold. The core thesis is that Stryker remains a high-quality med-tech franchise with a strong balance sheet and diversified revenue, but the recent revenue deceleration to 2.63% and margin compression warrant caution until there are signs of stabilization. The analyst consensus is 'buy' with an average target of $376.28, implying 36.6% upside, but these targets may be stale given the recent 20.6% one-month decline. The risk/reward is balanced: the forward PE of 16.46x is attractive, but the premium EV/EBITDA of 23.23x and PS of 5.35x leave little room for error.
Supporting evidence for a Hold includes: 1) The forward PE of 16.46x is below the trailing PE of 41.40x, suggesting the market expects earnings growth, but the PEG ratio of 5.16 indicates the stock is not cheap on growth-adjusted terms. 2) Revenue growth has decelerated to 2.63% in Q1 2026 from double-digit levels in prior quarters, a significant slowdown. 3) Profitability remains solid with a net margin of 12.38% and ROE of 14.48%, but margins are compressing. 4) Free cash flow of $4.571 billion provides a 3.4% yield, supporting the dividend and buybacks, but Q1 FCF did not cover shareholder returns. 5) The implied upside to the average analyst target is 36.6%, but the low target of $315.00 implies only 14.3% upside, indicating limited margin of safety.
The biggest risks that could invalidate the Hold rating are: 1) A further deceleration in revenue growth below 2% or negative growth, which would likely trigger multiple compression. 2) Continued margin erosion, particularly if gross margin falls below 63%. 3) A breakdown below the 52-week low of $267.00, which could lead to a technical selloff. The rating would upgrade to Buy if revenue growth reaccelerates above 5% and margins stabilize, or if the stock drops below $250, offering a more attractive entry point. It would downgrade to Sell if revenue growth turns negative or if operating margin falls below 15%. Relative to its history, the stock is undervalued on a forward PE basis but fairly valued on EV/EBITDA; relative to peers, it trades at a premium that is hard to justify with current growth.
Sign up to view all
SYK 12-Month Price Forecast
The forward-looking view is neutral with medium confidence. Stryker's fundamental story is at an inflection point: the revenue slowdown and margin compression are concerning, but the discounted forward PE and substantial analyst upside suggest the selloff may be overdone. The base case (55% probability) sees the stock stabilizing in the $300-$350 range as growth remains sluggish but positive. A reacceleration in revenue growth above 5% would likely trigger a bullish re-rating, while a further deceleration below 2% could lead to a bearish breakdown. Key developments to watch include Q2 2026 earnings, gross margin trends, and analyst revisions. I would upgrade to bullish if revenue growth accelerates and margins stabilize, and downgrade to bearish if growth turns negative or the stock breaks below $267.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Stryker Corporation's 12-month outlook, with a consensus price target around $376.28 and implied upside of +33.5% versus the current price.
Average Target
$376.28
0 analysts
Implied Upside
+33.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$315 - $465
Analyst target range
Coverage is robust, with 25 analysts covering Stryker and a consensus recommendation of "buy" (recommendation mean of 1.68 on a 1-5 scale where 1 is strong buy). The average target price of $376.28 implies approximately 36.6% upside from the current price of $275.56 — an unusually large implied return that reflects either significant undervaluation or stale targets that have not yet been revised downward following the recent collapse. The consensus leans clearly bullish, with the institutional ratings list showing predominantly Outperform/Overweight/Buy actions from BMO Capital, Evercore ISI, Leerink, Barclays, JP Morgan, Canaccord, Wells Fargo, and Needham, and only Truist Securities maintaining a Hold — but the critical caveat is that most of these ratings were issued in May-July 2026, before the September price collapse, meaning the consensus may be lagging the market's repricing. The target range is very wide, from a low of $315.00 to a high of $465.00 — a spread of $150, or roughly 48% of the low target — which signals high uncertainty and weak conviction among analysts. The high target of $465.00 implies roughly 69% upside and would require a full recovery to above the 52-week high of $392.55, assuming multiple expansion back toward historical med-tech premium levels plus a reacceleration of revenue growth toward high single digits; this scenario likely embeds successful integration of the Amplitude Vascular acquisition and a rebound in procedure volumes. The low target of $315.00 still implies 14.3% upside from the current price, which is notable because even the most bearish analyst target sits above the current price — suggesting the selloff may be overdone relative to fundamental coverage, though the low target also implies the bear case is a growth stall rather than a collapse. The recent upgrade pattern (BMO Capital moving to Outperform from Market Perform on July 9, 2026) is a mildly positive signal, but with the stock down 20.6% in the past month, the risk is that these targets are revised lower in coming weeks, which would remove the current apparent margin of safety and could pressure shares further.
Drowning in data?
Find the real signal!
Bulls vs Bears: SYK Investment Factors
The bear case currently has stronger evidence due to the sharp revenue deceleration to 2.63% and accelerating negative momentum, which suggest fundamental deterioration rather than a temporary dip. However, the bull case rests on the deeply discounted forward PE of 16.46x and substantial analyst upside, implying the market may have overreacted. The single most important tension is whether the revenue slowdown is a temporary blip or the start of a sustained low-growth era; if growth reaccelerates, the stock could re-rate sharply, but if it stalls, the premium valuation will likely compress further. Near-term, the technical picture is bearish with the stock near its 52-week low, but the risk/reward for long-term investors is becoming more balanced.
Bullish
- Deeply discounted forward valuation: SYK trades at a forward PE of 16.46x based on consensus EPS of $23.11, a level typically reserved for low-growth industrials, not a premium med-tech compounder. This multiple implies the market is pricing in a severe earnings slowdown that may not materialize given the company's diversified franchise.
- Analyst targets imply substantial upside: The average analyst target of $376.28 offers 36.6% upside from the current price of $275.56, and even the lowest target of $315.00 implies 14.3% upside. With 25 analysts and a consensus 'buy' rating (mean 1.68), the selloff appears overdone relative to fundamental coverage.
- Strong balance sheet and cash generation: Debt-to-equity of 0.73 and a current ratio of 1.89 provide financial flexibility, while trailing free cash flow of $4.571 billion yields 3.4% on the $134.3 billion market cap. This supports continued dividends and bolt-on M&A, such as the Amplitude Vascular acquisition.
- Low beta offers relative stability: With a beta of 0.768, SYK is roughly 23% less volatile than the broader market, meaning the recent 29% decline is largely idiosyncratic rather than systematic. This suggests the selloff may be overdone and provides a cushion for long-term holders.
Bearish
- Severe revenue growth deceleration: Q1 2026 revenue grew just 2.63% year over year to $6.02 billion, a sharp slowdown from 11.4% in Q4 2025 and 10.3% in Q3 2025. This deceleration is the core fundamental concern and suggests the growth engine has stalled.
- Margin compression across the board: Gross margin fell to 63.29% in Q1 2026 from 65.22% in Q4 2025, while operating margin plunged to 15.55% from 27.35% in Q4 2025. Net margin also declined to 12.38% from 14.68% in Q2 2025, indicating profitability is under pressure.
- Premium valuation hard to justify: Despite the forward PE looking low, SYK's EV/EBITDA of 23.23x and PS ratio of 5.35x are at a premium to large-cap med-tech peers (typically 15-20x EV/EBITDA). With growth at 2.6%, this premium is increasingly difficult to defend.
- Accelerating negative price momentum: The stock is down 20.64% in the past month, worse than the 11.74% decline over three months, indicating selling pressure is accelerating. The recent gap-down from $303.13 to $276.43 on September 8 suggests a fundamental repricing.
SYK Technical Analysis
Stryker is in a pronounced downtrend, with the current price of $275.56 sitting just 2.1% above its 52-week low of $267.00 and a staggering 29.8% below its 52-week high of $392.55 — meaning the stock is trading at only about 70% of its 52-week range. The 1-year price change of -29.12% versus the S&P 500's +16.22% represents roughly 45 percentage points of relative underperformance, one of the most severe divergences in large-cap med-tech. This positioning near the bottom of the range is a classic falling-knife setup: while it screens as a value opportunity on price alone, the absence of any stabilization suggests sellers remain in control and catching the bottom carries substantial risk. Recent momentum has deteriorated dramatically rather than stabilized. The 1-month change of -20.64% is far worse than the 3-month change of -11.74% and the 6-month change of -18.18%, indicating that selling pressure is accelerating, not abating — a bearish acceleration pattern. The most alarming datapoint is the single-week collapse from $303.13 on September 4 to $276.43 on September 8, a roughly 8.8% gap-down that occurred on elevated volume (most recent session volume of 3.72 million shares), suggesting a fundamental or news-driven repricing rather than routine profit-taking. The relative strength readings confirm the divergence: -19.58% versus SPY over 1 month and -45.34% over 1 year, meaning Stryker is not merely falling but falling while the market rises. Key technical levels are now clearly defined and unusually close together. Immediate support sits at the 52-week low of $267.00, only 3.1% below the current price — a break below that level would open the door to price discovery with no historical reference point, a scenario that typically triggers momentum-driven selling. Resistance is layered: the $303-$307 area (the early-September breakdown zone) is the first hurdle, followed by the $330-$340 region where the stock consolidated in July and August, and ultimately the $392.55 52-week high. Notably, Stryker's beta of 0.768 means it is roughly 23% less volatile than the broader market, which is a double-edged sword here: it implies the -29% decline is not simply high-beta amplification but a genuine idiosyncratic de-rating, and it suggests position sizing can be somewhat larger than a high-beta name for equivalent risk, though the current drawdown of -31.53% from peak shows that low beta offers little protection in a stock-specific selloff.
Beta
0.77
0.77x market volatility
Max Drawdown
-31.5%
Largest decline past year
52-Week Range
$267-$393
Price range past year
Annual Return
-26.5%
Cumulative gain past year
| Period | SYK Return | S&P 500 |
|---|---|---|
| 1m | -16.9% | -2.0% |
| 3m | -9.2% | +1.4% |
| 6m | -18.5% | +15.0% |
| 1y | -26.5% | +15.7% |
| ytd | -19.0% | +11.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SYK Fundamental Analysis
Stryker's revenue trajectory has decelerated meaningfully. Q1 2026 (period ending 2026-03-31) revenue came in at $6.02 billion, up just 2.63% year over year from $5.866 billion in Q1 2025 — a sharp slowdown from the prior-year quarterly cadence, where Q4 2025 revenue of $7.171 billion grew 11.4% over Q4 2024's $6.436 billion and Q3 2025's $6.057 billion grew 10.3% over Q3 2024's $5.494 billion. The sequential trend is also soft: Q1 2026's $6.02 billion is essentially flat versus Q2 2025's $6.022 billion and below Q3 2025's $6.057 billion, suggesting the growth engine has stalled rather than merely lapped a tough comparison. Segment data shows MedSurg at $3.207 billion and Orthopaedics at $2.813 billion, a relatively balanced mix, but with only two segments disclosed and no prior-period segment comparison provided, the data does not allow precise attribution of which line is dragging — though the overall 2.6% growth rate is well below Stryker's historical high-single-digit trajectory and is the single most important fundamental concern in this dataset. Profitability remains solid but is showing signs of pressure. Q1 2026 net income was $745 million on $6.02 billion of revenue, a net margin of 12.38%, down from 14.68% in Q2 2025 and 14.18% in Q3 2025, though above the 11.15% recorded in Q1 2025. Gross margin in Q1 2026 was 63.29%, down from 65.22% in Q4 2025 and 63.60% in Q3 2025, while the trailing gross margin of 63.96% remains healthy for med-tech but is compressing. Operating income of $936 million in Q1 2026 equates to a 15.55% operating margin, a steep drop from 27.35% in Q4 2025 and 18.74% in Q3 2025 — the Q4 figure benefited from seasonality and a favorable tax line, but the sequential compression is real and reflects both gross margin pressure and a $2.281 billion SG&A load plus $413 million in R&D spending. The balance sheet and cash flow picture is the strongest part of the fundamental story. Debt-to-equity stands at 0.73, current ratio at 1.89, and ROE at 14.48% — all reasonable for a large-cap med-tech, though the Q1 2026 cash flow statement shows the company repaid $1.0 billion of debt and paid $337 million in dividends while generating only $581 million in operating cash flow and $415 million in free cash flow, a quarter where FCF did not cover shareholder returns. Trailing twelve-month free cash flow of $4.571 billion against a $134.3 billion market cap implies an FCF yield of roughly 3.4%, which is modest but supported by the company's investment-grade profile; the key risk is that if revenue growth stays in the low single digits, the combination of $166 million quarterly capex, $337 million dividends, and debt service will increasingly constrain the bolt-on M&A strategy that has historically driven Stryker's growth.
Quarterly Revenue
$6.0B
2026-03
Revenue YoY Growth
+2.6%
YoY Comparison
Gross Margin
63.3%
Latest Quarter
Free Cash Flow
$4.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SYK Overvalued?
Because Stryker is solidly profitable — Q1 2026 net income of $745 million and trailing EPS of $0.024 (reflecting a data anomaly in the trailing figure, with the more reliable quarterly diluted EPS at $1.93) — the PE ratio is the appropriate primary metric. The trailing PE of 41.40x versus a forward PE of 16.46x is an extraordinarily wide gap, implying the market expects a massive earnings inflection; however, this gap is largely an artifact of the distorted trailing EPS figure, and the more meaningful read is the forward PE of 16.46x against consensus estimated EPS of $23.11, which prices Stryker at a level more typical of a low-growth industrial than a premium med-tech compounder. The forward multiple's compression is the market's way of saying it does not believe the consensus growth trajectory. On peer comparison, Stryker's price-to-sales ratio of 5.35x and EV/EBITDA of 23.23x sit at a premium to the broader medical devices sector, where large-cap peers typically trade in the 15-20x EV/EBITDA range — implying a roughly 15-50% premium depending on the peer set. That premium is historically justified by Stryker's above-market growth and best-in-class OR equipment franchise, but with revenue growth now at 2.63% and gross margins compressing to 63.29%, the premium is increasingly difficult to defend; the PB ratio of 5.99x and PEG ratio of 5.16 further suggest the stock is not cheap on growth-adjusted terms despite the headline forward PE looking reasonable. Historically, Stryker's PE has ranged from roughly 24.9x (Q4 2023) to 62.9x (Q4 2024) on the distorted trailing basis, with the more normal range in the high-30s to mid-40s; the current trailing PE of 41.40x sits mid-range, while the PS ratio of 5.35x is well below the 20-25x range seen in 2024-2025 historical data (though that historical PS series appears to use a different share-count basis and is not directly comparable). The critical historical takeaway is that Stryker's PB ratio has compressed from 7.14x in Q2 2025 to 5.99x now, and its dividend yield has risen to 0.96% from roughly 0.21-0.27% in prior periods — a signal that the price decline has pushed the stock toward the lower end of its own valuation band, which historically has been an attractive entry point but only when growth subsequently reaccelerated.
PE
41.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 38x~46x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
23.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are mounting. The most immediate concern is the sharp deceleration in revenue growth to just 2.63% year over year in Q1 2026, down from 11.4% in Q4 2025, which threatens the company's ability to support its premium valuation. Margin compression is evident: gross margin fell to 63.29% from 65.22% in Q4 2025, and operating margin dropped to 15.55% from 27.35%, partly due to a $2.281 billion SG&A load and $413 million in R&D spending. Additionally, Q1 2026 free cash flow of $415 million did not cover the $337 million in dividends and $1.0 billion debt repayment, highlighting a potential cash flow mismatch if growth remains weak. The debt-to-equity ratio of 0.73 is manageable, but the company's reliance on bolt-on M&A to drive growth could be constrained if cash flow remains under pressure.
Market and competitive risks are significant. SYK's EV/EBITDA of 23.23x and PS ratio of 5.35x are at a premium to the broader medical devices sector, which typically trades at 15-20x EV/EBITDA. If growth fails to reaccelerate, multiple compression could continue, especially as the stock has already fallen 29% in the past year. The beta of 0.768 indicates lower volatility than the market, but the recent idiosyncratic selloff shows that low beta offers little protection in a stock-specific downturn. Competitive threats from Zimmer Biomet, Johnson & Johnson MedTech, and Boston Scientific persist, and the recent underwhelming trial results from Boston Scientific (March 2026) highlight the sector's sensitivity to clinical data. Regulatory and tariff uncertainties also loom, particularly given that roughly one-fourth of revenue comes from outside the US.
The worst-case scenario involves a continued revenue slowdown, further margin erosion, and a breakdown below the 52-week low of $267.00. If Q2 2026 earnings miss expectations and analysts revise targets downward, the stock could test the bear-case target of $315.00 (which is actually above the current price, but if sentiment worsens, it could fall to $250 or lower). From the current price of $275.56, a drop to the 52-week low of $267.00 represents a 3.1% decline, but a more severe scenario could see the stock fall to $230-$240, a 13-17% decline, if the market prices in a recession-like scenario for med-tech. The max drawdown of -31.53% from peak already shows the potential for significant losses, and without a clear catalyst for growth, the stock could remain under pressure.
FAQ
The key risks include: 1) Financial risk: revenue growth has decelerated to 2.63% year over year, and margins are compressing, with operating margin falling to 15.55% in Q1 2026 from 27.35% in Q4 2025. 2) Competitive risk: Stryker faces intense competition from Zimmer Biomet, J&J MedTech, and Boston Scientific, and any product missteps could lead to market share loss. 3) Macro risk: with roughly one-fourth of revenue from outside the US, tariff and currency headwinds could pressure results. 4) Valuation risk: the stock trades at a premium EV/EBITDA of 23.23x, and if growth doesn't reaccelerate, multiple compression could continue. The most severe risk is a sustained low-growth environment that forces analysts to revise targets downward, potentially pushing the stock below $267.
Our 12-month forecast presents three scenarios: Bull case (25% probability) targets $376-$465, assuming revenue growth reaccelerates above 5% and margins stabilize, driven by new product launches and successful M&A integration. Base case (55% probability) targets $300-$350, with growth stabilizing in the low single digits and the stock trading in a range. Bear case (20% probability) targets $267-$300, assuming continued deceleration, margin erosion, and a break below the 52-week low. The base case is most likely, hinging on whether revenue growth can stay above 2% and margins hold. Key catalysts include Q2 2026 earnings and analyst revisions.
SYK appears undervalued on a forward PE basis but fairly valued to slightly overvalued on other metrics. The forward PE of 16.46x is significantly below the trailing PE of 41.40x and the broader market, suggesting the market expects earnings growth. However, the EV/EBITDA of 23.23x and PS ratio of 5.35x are at a premium to large-cap med-tech peers, which typically trade at 15-20x EV/EBITDA. The PEG ratio of 5.16 indicates the stock is not cheap relative to its growth rate. The market is pricing in a meaningful earnings recovery; if that fails to materialize, the stock could be overvalued. Relative to its own history, the PB ratio of 5.99x is below the 7.14x seen in Q2 2025, suggesting some undervaluation.
From a risk/reward perspective, SYK is a reasonable buy for long-term investors, but not without risks. The stock trades at a forward PE of 16.46x, well below its historical average, and the average analyst target of $376.28 implies 36.6% upside. However, the recent revenue slowdown to 2.63% and margin compression are red flags that could lead to further downside if not reversed. The biggest downside risk is a break below the 52-week low of $267.00, which could trigger a selloff to $230-$240. For investors with a long time horizon and tolerance for volatility, the current price offers an attractive entry point, but waiting for signs of revenue stabilization could reduce risk.
SYK is more suitable for long-term investment than short-term trading. The company is a diversified med-tech leader with a strong balance sheet, consistent free cash flow, and a growing dividend (yield 0.96%), making it a classic compounder. However, the stock is in a pronounced downtrend, with a beta of 0.768 and a 29% decline over the past year, indicating that near-term volatility could persist. Short-term traders might find opportunities on a break above $303-$307, but the risk of catching a falling knife is high. For long-term investors, a minimum holding period of 2-3 years is recommended to allow for a growth reacceleration and multiple recovery. The current price near the 52-week low offers a potentially attractive entry point for patient capital.
